|
|
News Breaks | | | | December 10, 2012 | | 10:35 EDT |  | ALXN | Alexion says data confirm long-term safety, efficacy of chronic Soliris therapy
Alexion Pharmaceuticals announced the presentation of new data demonstrating the long-term benefits of Soliris in patients with paroxysmal nocturnal hemoglobinuria, a debilitating, ultra-rare and life-threatening blood disorder. Data including the clinical benefits of Soliris in the treatment of patients with PNH and atypical hemolytic uremic syndrome were presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta. The company said ten-year data from a large cohort of patients with PNH from the United Kingdom confirm the long-term safety and efficacy of chronic Soliris therapy and demonstrate the impact of Soliris on quality of life. The long-term safety of Soliris was also demonstrated in PNH clinical development trials in which patients were treated continuously with Soliris and followed for up to 5.5 years and other Soliris data was presented as well. | |
|
News For ALXN From The Last 14 Days Check below for free stories on ALXN the last two weeks. |
|
|
| There are no results for ALXN |
|
|
|
|
|
|
